Effect of Acupressure on Interventional Pain in Infants
Launched by ISTANBUL UNIVERSITY - CERRAHPASA · Dec 21, 2021
Trial Information
Current as of June 04, 2025
Completed
Keywords
ClinConnect Summary
Aim: This study will be conducted in a randomized placebo-controlled research design to investigate the effect of acupressure, to be applied to the GB31 acupuncture point before the vaccinations, on interventional pain in infants (0-1 years) caused by the vaccine.
Introduction: As a non-pharmacological method originating from traditional Chinese medicine with a 5000-year history, acupressure is used in different parts of the world as a method of treatment (Gach, 1990, Pour, Ameri, Kazemi, \& Jahani, 2017). There are some points in the body that have great potential for energy transmission ...
Gender
ALL
Eligibility criteria
- Inclusion Criterias:
- • Being healthy
- • To be older than 4 weeks
- • To be less than 1 year old
- • Parents' consent to participate in the study
- • To be born between 38-42 gestational weeks
- • To take part in the routine vaccination program of the Ministry of Health
- Exclusion Criterias:
- • Being a sick infant
- • To be over 1 year old
- • Have taken analgesics in the last 4 hours
- • To be born lower than 37 gestational weeks
- • Parents' don't consent to participate in the study
About Istanbul University Cerrahpasa
Istanbul University - Cerrahpasa is a prestigious academic institution renowned for its commitment to advancing medical research and education. With a focus on innovative clinical trials, the university harnesses cutting-edge methodologies to address pressing health challenges. Its collaborative environment fosters interdisciplinary research, enabling the development of effective therapeutic strategies and enhancing patient care. The institution's dedication to ethical standards and patient safety underscores its reputation as a leader in clinical research within the region and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Istanbul, , Turkey
Patients applied
Trial Officials
Duygu GÖZEN, Ph.D
Principal Investigator
Istanbul University - Cerrahpasa
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials